United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

21 Oct 2016
Change (% chg)

$-0.10 (-0.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Blight, Andrew 

Dr. Andrew R. Blight, Ph.D., is Chief Scientific Officer of Acorda Therapeutics, Inc., since January 2004. He previously served as our Executive Vice President, Research and Development from 2000 to 2004, and Vice President, Research and Development, from 1998 to 2000. Prior to joining Acorda Therapeutics, he spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. Dr. Blight held prior academic positions at Purdue University and New York University. Dr. Blight is a leader in SCI pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials. Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the NIH NSDA review committee. He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society. Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.

Basic Compensation

Total Annual Compensation, USD 583,723
Restricted Stock Awards, USD 229,973
Long-Term Incentive Plans, USD --
All Other, USD 670,864
Fiscal Year Total, USD 1,484,560

Options Compensation

  Quantity Market Value
Exercisable 108,205 950,313.00
Unexercisable 39,255 151,524.00
Exercised 19,296 679,512.00
Name Fiscal Year Total

Ron Cohen


David Lawrence


Andrew Blight


Jane Wasman


Burkhard Blank


Andrew Hindman

As Of  30 Dec 2014